

List the top 2-3 takeaways from your breakout discussions. Please list your group number in your response.

Clear need for program /portfolio level strategy - Broad sources of data that can inform the strategy Move from High level epi data to more local data - community and patients

(group 2) 2. Under Infrastructure: include how the patient experience informs / identifies stakeholders, generating baselines (complex, varies), and this is an iterative learning process

Group 3 Integrated approach re measuring clinical trial value and taking it back to clinical care, Ability to measure demographic data Establish a baseline regardless of organizational size Measure PROM/experience/engagement

(group 2)3. Current sponsor focus. Add perspectives for sites, academia, advocacy, etc - all partners need to know how / when to add input.

Group 2: Community and Patient Engagement1. Two separate rows: Community Infrastructure and Patient Engagement

Group 3 Measure geographic participation/distribution Measuring retention and enrollment, therapeutic and non-therapeutic and across therapeutic areas.